Particle bombardment technology, also known as biological biolistics or bioballistics, is a nonviral, physical gene delivery method in which target cells are transfected using DNA-coated particles. Cornell University horticultural scientist John Sanford and cohorts developed the technique in the early 1980s. The technology is a very effective gene delivery method for plant cells, as it […]
Santa Clara, CA 7/24/08—Affymetrix has purchased a developer of digitally encoded microparticle technology for $25 million in cash. GenomeWeb.com reports that the company is True Materials and that Randy True, the company’s vice president of R&D, has joined Affymetrix. Affymetrix stated that the technology will allow it to enter the low to mid-multiplexing markets and […]
San Diego, CA 7/22/08—Illumina has acquired Avantome, the developer of a long read-length sequencing technology, for $25 million in cash and contingent payments of up to $35 million. Avantome’s principal founders Mostafa Ronaghi and Helmy Eltoukhy will join Illumina. Dr. Ronaghi will serve as senior vice president and chief technical officer and Dr. Eltoukhy will […]
Company Announcements Dynisco restructured in March, creating divisions to serve specific market segments, including Plastics, Rubber and Industrial, Oil and Gas, Life Sciences, and Test and Control. Under an OEM agreement, Digital Light will supply REOLOGICA with photocuring accessories. In April, Anton Paar GmbH announced the appointment of Dr. Othmar Ederer, general director of the […]
Austin, TX 7/7/08—Xenemetrix announced that on June 15 it acquired Jordan Valley’s Analytical Instrument Division, which suppliers energy dispersive–X-ray fluorescence spectroscopy instruments (ED-XRF). Xenemetrix was formed by a private management group, led by CEO Doron Reinis, a founding partner of Business Processes, a consulting, production engineering and industrial engineering services firm. “As Jordan Valley Semiconductors […]
Growth for India’s biotech sector has decelerated from the compound annual growth rate of 34% in the past five years to a 20% rate for 2007–2008, recording nearly $2.5 billion in revenues, according to a survey by the Association of Biotech Led Enterprises and Biospectrum magazine. The biotech sector is divided into five segments: biopharma, […]
In a development that observers deemed a significant action for US product safety regulations, the US Congress passed the Consumer Product Safety Improvement Act of 2008 this month. The bill has been sent to President Bush, who is expected to sign it into law, lowers allowable limits for lead and for six types of phthalates […]
Despite the economic downturn, sales of analytical and life science instruments and related aftermarket products and service have remained healthy. Steady industrial end-markets, demand from Asia, and robust biotech and contract research organization (CRO) sales have offset cautious spending by big pharma and a mixed academic market. As the table on page 3 shows, first-half […]
Foster City, CA 7/1/08—Applera completed the spin off of Celera on June 1 (see IBO 2/29/08) and changed its name to Applied Biosystems.
Midland, MI 7/10/08; Philadelphia, PA 7/10/08—Specialty chemicals firm Rohm and Haas has agreed to be acquired by Dow for $78 per share in cash, a 48% premium to the stock’s 60-day average closing price, in a deal valued at $15.3 billion. Both Rohm and Haas and Dow are suppliers of resins for ion exchange chromatography. […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
